Mechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells

Conference item


Bennacer, A., Roberts, H. and Stordal, B. 2018. Mechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
TitleMechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells
AuthorsBennacer, A., Roberts, H. and Stordal, B.
Abstract

Introduction: Ovarian Cancer is the most lethal gynaecologic malignancy, with epithelial ovarian cancer accounting for around 90% of all cases. Most patients present with advanced stage disease at the time of diagnosis, resulting in a poor prognosis and a 30% 5-year survival rate. Treatment is usually comprised of surgery and combination chemotherapy, most commonly using carboplatin and taxol, but one of the major contributing factors to the disease’s poor prognosis is chemoresistance. Several cellular pathways have been found to be involved in chemoresistance, but their mechanisms of action are still not fully understood. PLAC8, MAP3K15, Bcl-2 and Bcl-xl have been previously identified as anti-apoptotic proteins of interest, due to their overexpression in carboplatin- and taxol-resistant cell lines. Interestingly, PLAC8 has also been found to be involved in autophagy, suggesting the potential involvement of autophagy in ovarian cancer chemoresistance. This research aims to further investigate the role of both apoptosis and autophagy in ovarian cancer chemoresistance, through measuring gene expression, protein expression and the effects of gene knockdown on drug sensitivity, apoptosis and autophagy in an ovarian cancer cell line. This is the first time PLAC8 will be investigated in ovarian cancer chemoresistance, providing novel research to aid in the understanding of its mechanism of action. Quantitative PCR (qPCR) was used to analyse the gene expression of previously identified genes of interest, including PLAC8, MAP3K15, Bcl-2 and Bcl-xl, in the following ovarian cancer cell lines:- UPN251 (sensitive to chemotherapy), UPN251-7C (carboplatin-resistant) and UPN251-7T (taxol-resistant). Western blots will be run to confirm the presence or absence of these proteins of interest in the 3 cell lines, both with and without drug treatment. MAP3K15 and PLAC8 expression was found to be significantly increased (~7-fold ±1; p<0.001 and ~8-fold ±1.6; p<0.001, respectively) in the 2 chemoresistant cell lines compared to the chemosensitive cell line. The protein expression of PLAC8 was found to be consistent with its increased gene expression in the chemoresistant cell lines, suggesting the involvement of PLAC8 in ovarian cancer chemoresistance. Since PLAC8 has been found to be linked with autophagy, the involvement of previously identified autophagy markers will also be investigated through gene and protein analysis.

Sustainable Development Goals3 Good health and well-being
Middlesex University ThemeHealth & Wellbeing
Research GroupBiomarkers for Cancer group
LanguageEnglish
ConferenceResearch Degrees Students' Summer Conference
Publication dates
Print04 Sep 2018
Publication process dates
Deposited25 Jul 2022
Accepted04 Aug 2018
Output statusPublished
Permalink -

https://repository.mdx.ac.uk/item/89xyx

  • 44
    total views
  • 0
    total downloads
  • 3
    views this month
  • 0
    downloads this month

Export as

Related outputs

Ovarian cancer: identifying and managing familial and genetic risk
Slade, E., Berg, L., Dworzynski, K., Manchanda, R., Barber, V., Bowen, R., Brentnall, A., Cameron, A., Davies, D., Davies, M., Evans, D., Hayward, J., McCluggage, W., Miles, T., Monahan, K., Moses, D., Robb, F., Rosenthal, A., Side, L., Stanford, J., Stordal, B. and Tripathi, V. 2024. Ovarian cancer: identifying and managing familial and genetic risk. National Institute for Health and Care Excellence.
Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance
Slade, E., Berg, L., Dworzynski, K., Manchanda, R., Barber, V., Bowen, R., Brentnall, A., Cameron, A., Davies, D., Davies, M., Evans, D., Hayward, J., McCluggage, W., Miles, T., Monahan, K., Moses, D., Robb, F., Rosenthal, A., Side, L., Stanford, J., Stordal, B. and Tripathi, V. 2024. Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance. British Medical Journal (The BMJ). 385. https://doi.org/10.1136/bmj.q807
Identifying fibroblast growth factor receptor 3 as a mediator of periosteal osteochondral differentiation through the construction of microRNA-based interaction networks
Wells, L., Roberts, H., Luyten, F. and Roberts, S. 2023. Identifying fibroblast growth factor receptor 3 as a mediator of periosteal osteochondral differentiation through the construction of microRNA-based interaction networks. Biology. 12 (11). https://doi.org/10.3390/biology12111381
A machine learning‑based image segmentation method to quantify in vitro osteoclast culture endpoints
Davies, B.K., Hibbert, A.P., Roberts, S.J., Roberts, H., Tickner, J.C., Holdsworth, G., Arnett, T.R. and Orriss, I.R. 2023. A machine learning‑based image segmentation method to quantify in vitro osteoclast culture endpoints. Calcified Tissue International and Musculoskeletal Research. 113 (4), p. 437–448.
Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population
Radu, C., Matos de Melo Fernandes, N., Khalfe, S. and Stordal, B. 2023. Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population. Cancer Medicine. 12 (8), pp. 9879-9892. https://doi.org/10.1002/cam4.5670
Establishment and characterization of single and triple‐agent resistant osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2023. Establishment and characterization of single and triple‐agent resistant osteosarcoma cell lines. Advanced Biology. 7 (2). https://doi.org/10.1002/adbi.202200194
Breastfeeding reduces the risk of breast cancer: a call for action in high-income countries with low rates of breastfeeding
Stordal, B. 2023. Breastfeeding reduces the risk of breast cancer: a call for action in high-income countries with low rates of breastfeeding. Cancer Medicine. 12 (4), pp. 4616-4625. https://doi.org/10.1002/cam4.5288
The role of autophagy in canine osteosarcoma chemoresistance and metastasis
Kulatheepan, Y., Baines, S., Meeson, R. and Roberts, H. 2022. The role of autophagy in canine osteosarcoma chemoresistance and metastasis. 26th Annual Technological Advances in Science, Medicine and Engineering Conference 2022. Virtual
ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment
Pereira, J., Roberts, S. and Roberts, H. 2022. ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment. Research Students' Summer Conference. Middlesex University, Lonon, UK 22 - 23 Jun 2022
Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis
Paternina Martinez, D., Roberts, S. and Roberts, H. 2022. Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis. Research Students' Summer Conference. Middlesex University, Lonon, UK 22 - 23 Jun 2022
CRISPR/Cas9-mediated ATG7 knockout results in enhanced osteosarcoma chemosensitivity
Pears, A. and Roberts, H. 2022. CRISPR/Cas9-mediated ATG7 knockout results in enhanced osteosarcoma chemosensitivity. Bone Research Society Annual Conference. Manchester Metropolitan Univeristy 06 - 08 Jul 2022
ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment
Pereira, J., Roberts, S. and Roberts, H. 2022. ATR inhibition increases sensitivity of a highly aggressive osteosarcoma cell line to cisplatin treatment. Bone Research Society Annual Conference. Manchester Metropolitan Univeristy 06 - 08 Jul 2022
Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis
Paternina Martinez, D., Roberts, S. and Roberts, H. 2022. Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis. Bone Research Society Annual Conference. Manchester Metropolitan Univeristy 06 - 08 Jul 2022
Intentionality for inclusivity - the journey at Middlesex University
Roberts, H., Punev, I., Allardyce, D., Kyprianou, A., Appiah, S., Megeney, A., Calin, A., Gallacher, D. and Mill, R. 2022. Intentionality for inclusivity - the journey at Middlesex University. McGraw Hill.
Biomedical Science Exchanges at Middlesex University London
Stordal, B. 2019. Biomedical Science Exchanges at Middlesex University London. REALISE: Seminar on International Staff Mobility. Universities UK Boardroom, Woburn House, WC1H 9HQ, London
Biomedical Science Exchanges
Stordal, B. 2018. Biomedical Science Exchanges. Middlesex University’s Erasmus Staff Training Week 2018. Middlesex University London
Biomedical Science Exchanges
Stordal, B. 2018. Biomedical Science Exchanges. Middlesex University Staff Conference 2018: Learning through Change. Middlesex University London 27 Mar 2018
Comparison of formative multiple choice questions using online platforms vs summative assessment: experience from an anatomy and physiology module
Stordal, B. 2015. Comparison of formative multiple choice questions using online platforms vs summative assessment: experience from an anatomy and physiology module. Middlesex University Annual Learning and Teaching Conference 2015: Revisiting Assessment. Middlesex University, London, United Kingdom 13 Jul 2015
Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy
Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. 2018. Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
ROR1-A novel biomarker for chemoresistance in ovarian cancer
Shafat, E., Hills, F. and Stordal, B. 2018. ROR1-A novel biomarker for chemoresistance in ovarian cancer. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
Optimisation of a selection strategy for drug resistance osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2018. Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (Review)
Patel, A., Kalachand, R., Busschots, S., Doherty, B., Kapros, E., Lawlor, D., Hall, N. and Stordal, B. 2022. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (Review). Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD008766.pub3
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics guidance [DG34]
Nixon, F., Albrow, R., Donna, B., Kroese, D., Adair, E., Bagshaw, J., Carrol, E., Driskell, O., Edwards, S., Fleming, S., Gray, J., Halligan, S., Hitchman, J., Hyde, C., McGinley, P., Messenger, M., Moseley, A., Naylor, P., Neely, D., Rahman Haley, S., Richards, S., Sculpher, M., Stevenson, M., Summerton, N., Wierzbicki, A., Bramley, M., Graham, J., Pepper, L., Ryyan, D., Stordal, B., Van Mann, U. and Wardley, A. 2018. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics guidance [DG34]. NICE.
Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model
Stordal, B., Davey, M. and Davey, R. 2005. Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model. 96th AACR Annual Meeting. Anaheim California 16 - 20 Apr 2005 American Association for Cancer Research. pp. 348-349
Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: linking changes in genotype to the resistant phenotype
Stordal, B., Peters, G., St. Heaps, L. and Davey, R. 2006. Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: linking changes in genotype to the resistant phenotype. 97th AACR Annual Meeting. Washington D.C., USA 01 - 05 Apr 2006 American Association for Cancer Research. pp. 133
BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Stordal, B., Timms, K., Renuad, M., Thery, J., Farrelly, A., Williams, D., Potter, J., Tran, T., Korpanty, G., Cremona, M., Carey, M., Li, J., Li, Y., Aslan, O., O'Leary, J., Mills, G. and Hennessy, B. 2012. BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. 103rd Annual Meeting of the American Association for Cancer Research (AACR). Chicago 31 Mar - 04 Apr 2012 American Association for Cancer Research. https://doi.org/10.1158/1538-7445.AM2012-78
A systematic approach to the study of cancer stem cells applied to ovarian cancer
Ffrench, B., Cooke, A., Stordal, B., O'Toole, S., Sheils, O., Gallagher, M. and O'Leary, J. 2012. A systematic approach to the study of cancer stem cells applied to ovarian cancer. 103rd Annual Meeting of the American Association for Cancer Research (ACCR). Chicago, USA 31 Mar - 04 Apr 2012 American Association for Cancer Research. https://doi.org/10.1158/1538-7445.AM2012-3382
Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy
Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. 2018. Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy. 2018 NCRI Cancer Conference. Glasgow, Scotland 04 - 06 Nov 2018
ROR1- A biomarker for chemoresistance in ovarian cancer
Syed, E., Hills, F. and Stordal, B. 2018. ROR1- A biomarker for chemoresistance in ovarian cancer. 2018 NCRI Cancer Conference. Glasgow, Scotland 04 - 06 Nov 2018
Optimisation of a selection strategy for drug resistance osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2019. Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. 2019 NCRI Cancer Conference. Glasgow, UK 03 - 05 Nov 2019
The EMT­activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but predictive of survival
Rae, S., Keenan, J., Spillane, C., Blackshields, G., Madden, S. and Stordal, B. 2015. The EMT­activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but predictive of survival. 2015 NCRI Cancer Conference. Liverpool, UK 01 - 03 Nov 2015
BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data
Kalachand, R., Stordal, B., Madden, S., Chandler, B., Cunningham, J., Goode, E., Ruscito, I., Braicu, E., Sehouli, J., Ignatov, A., Yu, H., Katsaros, D., Lu, L., Mills, G., Broaddus, R., Lu, K., Carey, M., Timms, K., Rzepecka, I., Kupryjanczyk, J., Swisher, E., Harrell, M., Agnew, K., O'Riain, C., O'Toole, S., O'Leary, J., Thomas, D., Chaudhry, P., Srinivasan, R. and Hennessy, B. 2019. BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data. Lorne Cancer Conference. Lorne, Victoria, Australia 14 - 16 Feb 2019
Comparative selection strategies for development of platinum-drug resistant ovarian cancer cell lines
Busschots, S., Kalachand, R., O'Toole, S., O'Leary, J., Hennessy, B. and Stordal, B. 2017. Comparative selection strategies for development of platinum-drug resistant ovarian cancer cell lines. 12th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. Sydney, Australia 10 - 14 Dec 2017
PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC)
Kalachand, R., Cremona, M., Farrelly, A., Eustace, A., Stordal, B. and Hennessy, B. 2018. PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC). EACR25: The 25th Biennial Congress of the European Association for Cancer Research. Amsterdam, Netherlands 30 Jun - 03 Jul 2018
The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival
Rae, S., Spillane, C., Blackshields, G., Madden, S., Keenan, J. and Stordal, B. 2022. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival. Human Cell. 35 (5), pp. 1547-1559. https://doi.org/10.1007/s13577-022-00744-y
Decellularised cartilage ECM culture coatings drive rapid and robust chondrogenic differentiation of human periosteal cells
Vas, W., Shah, M., Roberts, H. and Roberts, S. 2022. Decellularised cartilage ECM culture coatings drive rapid and robust chondrogenic differentiation of human periosteal cells. Bioengineering. 9 (5), pp. 1-11. https://doi.org/10.3390/bioengineering9050203
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Klionsky, D., Roberts, H. and et al. 2021. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 17 (1), pp. 1-382. https://doi.org/10.1080/15548627.2020.1797280
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
Kalachand, R., O'Riain, C., Toomey, S., Carr, A., Timms, K., O'Toole, S., Madden, S., Bates, M., O'Leary, J., Gleeson, N., O'Donnell, D., Grogan, L., Breathnach, O., Farrelly, A., Stordal, B. and Hennessy, B. 2020. Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. Obstetrics & Gynecology Science. 63 (5), pp. 643-654. https://doi.org/10.5468/ogs.20033
BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis
Kalachand, R., Stordal, B., Madden, S., Chandler, B., Cunningham, J., Goode, E., Ruscito, I., Braicu, E., Sehouli, J., Ignatov, A., Yu, H., Katsaros, D., Mills, G., Lu, K., Carey, M., Timms, K., Kupryjanczyk, J., Rzepecka, I., Podgorska, A., McAlpine, J., Swisher, E., Bernards, S., O'Riain, C., O'Toole, S., O'Leary, J., Bowtell, D., Thomas, D., Prieske, K., Joosse, S., Woelber, L., Chaudhry, P., Häfner, N., Runnebaum, I. and Hennessy, B. 2020. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute. 112 (12), pp. 1190-1203. https://doi.org/10.1093/jnci/djaa070
Mapping human serum induced gene networks as a basis for the creation of biomimetic periosteum for bone repair
Al Hosni, R., Shah, M., Cheema, U., Roberts, H., Luyten, F. and Roberts, S. 2020. Mapping human serum induced gene networks as a basis for the creation of biomimetic periosteum for bone repair. Cytotherapy. 22 (8), pp. 424-435.
The combination of curcumin and doxorubicin shows a selective cytotoxic effect on acute myeloid leukaemia cell line
Hasan, N., Roberts, H., Ghali, L. and Appiah, S. 2018. The combination of curcumin and doxorubicin shows a selective cytotoxic effect on acute myeloid leukaemia cell line. NCRI Cancer Conference (2018). Glasgow, Scotland 04 - 06 Nov 2018
MicroRNA profiles are associated with lymphocyte count after a major traumatic injury: a potential role for immunometabolism?
Jones, T., Torrance, H., Roberts, H., Brohi, K., Barnes, M., Knight, J., Hinds, C., Ackland, G. and O'Dwyer, M. 2018. MicroRNA profiles are associated with lymphocyte count after a major traumatic injury: a potential role for immunometabolism? British Journal of Anaesthesia Research Forum. Royal College of Anaesthetists, London 30 - 31 May 2018 Elsevier. pp. e23-e24 https://doi.org/10.1016/j.bja.2018.05.027
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
Stordal, B., Kalachand, R. and Hall, N. 2018. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008766.pub2
CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy
Ffrench, B., Gasch, C., Hokamp, K., Spillane, C., Blackshields, G., Mahgoub, T., Bates, M., Kehoe, L., Mooney, A., Doyle, R., Doyle, B., O'Donnell, D., Gleeson, N., Hennessy, B., Stordal, B., O'Riain, C., Lambkin, H., O'Toole, S., O'Leary, J. and Gallagher, M. 2017. CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy. Cell Death & Disease. 8 (10). https://doi.org/10.1038/cddis.2017.379
Phytochemical modulation of apoptosis and autophagy: strategies to overcome chemoresistance in leukaemic stem cells in the bone marrow microenvironment
Owen, H., Appiah, S., Hasan, N., Ghali, L., Elayat, G. and Bell, C. 2017. Phytochemical modulation of apoptosis and autophagy: strategies to overcome chemoresistance in leukaemic stem cells in the bone marrow microenvironment. in: Zeng, B. and Zhao, K. (ed.) Neurobiology of Chinese Herb Medicine Elsevier.
Biomimetic strategies for fracture repair: engineering the cell microenvironment for directed tissue formation
Vas, W., Shah, M., Al Hosni, R., Owen, H. and Roberts, S. 2017. Biomimetic strategies for fracture repair: engineering the cell microenvironment for directed tissue formation. Journal of Tissue Engineering. 8, pp. 1-14. https://doi.org/10.1177/2041731417704791
Granulocyte macrophage colony-stimulating factor and interferon gamma act through different mechanisms in reversing post-operative immune suppression
Longbottom, E., Torrance, H., Owen, H., Hinds, C., Pearse, R. and O'Dywer, M. 2016. Granulocyte macrophage colony-stimulating factor and interferon gamma act through different mechanisms in reversing post-operative immune suppression. ESICM LIVES 2016: 29th Annual Congress of European Society of Intensive Care Medicine. Milan, Italy 01 - 05 Oct 2016 Springer. https://doi.org/10.1186/s40635-016-0098-x
Systemic inflammatory response syndrome after major abdominal surgery predicted by early upregulation of TLR4 and TLR5
Lahiri, R., Derwa, Y., Bashir, Z., Giles, E., Torrance, H., Owen, H., O'Dwyer, M., O'Brien, A., Stagg, A., Bhattacharya, S., Foster, G. and Alazawi, W. 2016. Systemic inflammatory response syndrome after major abdominal surgery predicted by early upregulation of TLR4 and TLR5. Annals of Surgery. 263 (5), pp. 1028-1037. https://doi.org/10.1097/SLA.0000000000001248
Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways
Longbottom, E., Torrance, H., Owen, H., Fragkou, P., Hinds, C., Pearse, R. and O'Dwyer, M. 2016. Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways. Annals of Surgery. 264 (2), pp. 370-377. https://doi.org/10.1097/SLA.0000000000001484
Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells
Stordal, B., Davey, M. and Davey, R. 2006. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemotherapy and Pharmacology. 58 (2), pp. 256-265. https://doi.org/10.1007/s00280-005-0148-7
T-helper cell polarisation following severe polytrauma
Torrance, H., Brohi, K., Warnes, G., Owen, H., Hinds, C., Pennington, D. and O'Dwyer, M. 2015. T-helper cell polarisation following severe polytrauma. ESICM LIVES 2015: 28th Annual Congress of European Society of Intensive Care Medicine. Berlin, Germany 03 - 07 Oct 2015 Springer Open. https://doi.org/10.1186/2197-425X-3-S1-A848
Post-operative immune suppression is reversible with interferon gamma and independent of IL-6 pathways
Longbottom, E., Torrance, H., Owen, H., Hinds, C., Pearse, R. and O'Dwyer, M. 2015. Post-operative immune suppression is reversible with interferon gamma and independent of IL-6 pathways. ESICM LIVES 2015: 28th Annual Congress of European Society of Intensive Care Medicine. Berlin, Germany 03 - 07 Oct 2015 Springer Open. https://doi.org/10.1186/2197-425X-3-S1-A820
The role of micrornas in the development of hospital acquired infection in polytrauma patients
Owen, H., Torrance, H., Barnes, M., Brohi, K., Knight, J., Hinds, C. and O'Dwyer, M. 2015. The role of micrornas in the development of hospital acquired infection in polytrauma patients. ESICM LIVES 2015: 28th Annual Congress of European Society of Intensive Care Medicine. Berlin, Germany 03 - 07 Oct 2015 Springer Open. https://doi.org/10.1186/2197-425X-3-S1-A35
Changes in gene expression following trauma are related to the age of transfused packed red blood cells
Torrance, H., Vivian, M., Brohi, K., Prowle, J., Pearse, R., Owen, H., Hinds, C. and O'Dwyer, M. 2015. Changes in gene expression following trauma are related to the age of transfused packed red blood cells. Journal of Trauma and Acute Care Surgery. 78 (3), pp. 535-542. https://doi.org/10.1097/TA.0000000000000534
The perioperative immune response
O'Dwyer, M., Owen, H. and Torrance, H. 2015. The perioperative immune response. Current Opinion in Critical Care. 21 (4), pp. 336-342. https://doi.org/10.1097/MCC.0000000000000213
Critical illness-induced bone loss is related to deficient autophagy and histone hypomethylation
Owen, H., Vanhees, I., Gunst, J., Van Cromphaut, S. and Van den Berghe, G. 2015. Critical illness-induced bone loss is related to deficient autophagy and histone hypomethylation. Intensive Care Medicine Experimental. 3. https://doi.org/10.1186/s40635-015-0052-3
Epigenetic regulatory pathways involving microRNAs may modulate the host immune response following major trauma
Owen, H., Torrance, H., Jones, T., Pearse, R., Hinds, C., Brohi, K. and O'Dwyer, M. 2015. Epigenetic regulatory pathways involving microRNAs may modulate the host immune response following major trauma. Journal of Trauma and Acute Care Surgery. 79 (5), pp. 766-772. https://doi.org/10.1097/TA.0000000000000850
Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines
Busschots, S., O'Toole, S., O'Leary, J. and Stordal, B. 2015. Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines. MethodsX. 2, pp. 8-13. https://doi.org/10.1016/j.mex.2014.11.002
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer
McEvoy, L., O'Toole, S., Spillane, C., Martin, C., Gallagher, M., Stordal, B., Blackshields, G., Sheils, O. and O'Leary, J. 2015. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC cancer. 15 (1). https://doi.org/10.1186/s12885-015-1539-8
Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells
Busschots, S., O'Toole, S., O'Leary, J. and Stordal, B. 2015. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. Experimental cell research. 336 (1), pp. 1-14. https://doi.org/10.1016/j.yexcr.2014.12.001
Humanized culture of periosteal progenitors in allogeneic serum enhances osteogenic differentiation and in vivo bone formation
Roberts, S., Owen, H., Tam, W., Solie, L., Van Cromphaut, S., Van den Berghe, G. and Luyten, F. 2014. Humanized culture of periosteal progenitors in allogeneic serum enhances osteogenic differentiation and in vivo bone formation. Stem Cells Translational Medicine. 3 (2), pp. 218-28. https://doi.org/10.5966/sctm.2012-0137
Perioperative blood transfusion is associated with a gene transcription profile characteristic of immunosuppression: a prospective cohort study
Fragkou, P., Torrance, H., Pearse, R., Ackland, G., Prowle, J., Owen, H., Hinds, C. and O'Dwyer, M. 2014. Perioperative blood transfusion is associated with a gene transcription profile characteristic of immunosuppression: a prospective cohort study. Critical Care. 18 (5). https://doi.org/10.1186/s13054-014-0541-x
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer
D’Adhemar, C., Spillane, C., Gallagher, M., Bates, M., Costello, K., Barry-O'Crowley, J., Haley, K., Kernan, N., Murphy, C., Smyth, P., O'Byrne, K., Pennington, S., Cooke, A., Ffrench, B., Martin, C., O'Donnell, D., Hennessy, B., Stordal, B., Finn, S., McCann, A., Gleeson, N., D'Arcy, T., Flood, B., O'Neill, L., Sheils, O., O'Toole, S. and O'Leary, J. 2014. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS ONE. 9 (6), pp. 1-15. https://doi.org/10.1371/journal.pone.0100816
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets
Madden, S., Clarke, C., Stordal, B., Carey, M., Broaddus, R., Gallagher, W., Crown, J., Mills, G. and Hennessy, B. 2014. OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Molecular Cancer. 13 (1), pp. 1-11. https://doi.org/10.1186/1476-4598-13-241
PARP inhibitors as P-glyoprotein substrates
Lawlor, D., Martin, P., Busschots, S., Thery, J., O'Leary, J.J., Hennessy, B.T. and Stordal, B. 2014. PARP inhibitors as P-glyoprotein substrates. Journal of Pharmaceutical Sciences. 103 (6), pp. 1913-1920. https://doi.org/10.1002/jps.23952
Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells
Doherty, B., Lawlor, D., Gillet, J., Gottesman, M., O'Leary, J. and Stordal, B. 2014. Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells. Anticancer Research. 34 (1), pp. 503-507.
In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies
McDermott, M., Eustace, A., Busschots, S., Breen, L., Crown, J., Clynes, M., O'Donovan, N. and Stordal, B. 2014. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Frontiers in Oncology. 4, pp. 1-16. https://doi.org/10.3389/fonc.2014.00040
Enhanced immunoreceptor tyrosine-based activation motif signaling is related to pathological bone resorption during critical illness
Vanhees, I., Gunst, J., Janssens, T., Wauters, A., Van Herck, E., Van Cromphaut, S., Van den Berghe, G. and Owen, H. 2013. Enhanced immunoreceptor tyrosine-based activation motif signaling is related to pathological bone resorption during critical illness. Hormone and Metabolic Research. 45 (12), pp. 862-9. https://doi.org/10.1055/s-0033-1351290
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Stordal, B., Timms, K., Farrelly, A., Gallagher, D., Busschots, S., Renaud, M., Thery, J., Williams, D., Potter, J., Tran, T., Korpanty, G., Cremona, M., Carey, M., Li, J., Li, Y., Aslan, O., O'Leary, J., Mills, G. and Hennessy, B. 2013. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Molecular Oncology. 7 (3), pp. 567-79. https://doi.org/10.1016/j.molonc.2012.12.007
Critical illness-related bone loss is associated with osteoclastic and angiogenic abnormalities
Owen, H., Vanhees, I., Solie, L., Roberts, S., Wauters, A., Luyten, F., Van Cromphaut, S. and Van den Berghe, G. 2012. Critical illness-related bone loss is associated with osteoclastic and angiogenic abnormalities. Journal of Bone and Mineral Research. 27 (7), pp. 1541-1552. https://doi.org/10.1002/jbmr.1612
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein
Stordal, B., Hamon, M., McEneaney, V., Roche, S., Gillet, J., O'Leary, J., Gottesman, M. and Clynes, M. 2012. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS ONE. 7 (7), pp. 1-13. https://doi.org/10.1371/journal.pone.0040717
Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer
Dudziec, E., Miah, S., Choudhry, H., Owen, H., Blizard, S., Glover, M., Hamdy, F. and Catto, J. 2011. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clinical Cancer Research. 17 (6), pp. 1287-1296. https://doi.org/10.1158/1078-0432.CCR-10-2017
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review
Murphy, M. and Stordal, B. 2011. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resistance Updates. 14 (3), pp. 177-190. https://doi.org/10.1016/j.drup.2011.02.004
Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells
Egan, K., Crowley, D., Smyth, P., O'Toole, S., Spillane, C., Martin, C., Gallagher, M., Canney, A., Norris, L., Conlon, N., McEvoy, L., Ffrench, B., Stordal, B., Keegan, H., Finn, S., McEneaney, V., Laios, A., Ducrée, J., Dunne, E., Smith, L., Berndt, M., Sheils, O., Kenny, D. and O'Leary, J. 2011. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS ONE. 6 (10). https://doi.org/10.1371/journal.pone.0026125
Low frequency of epigenetic events in urothelial tumours from young patients
Catto, J., Owen, H., Giedl, J., Wild, P., Fine, S., Epstein, J., Humphrey, P., Dehner, L., Amin, M., Blaszyk, H., Hughes, D., Hartmann, A. and Stoehr, R. 2010. Low frequency of epigenetic events in urothelial tumours from young patients. European Urology Supplements. 9 (2), pp. 260-261. https://doi.org/10.1016/S1569-9056(10)60798-1
Low frequency of epigenetic events in urothelial tumors in young patients
Owen, H., Giedl, J., Wild, P., Fine, S., Humphrey, P., Dehner, L., Amin, M., Epstein, J., Blaszyk, H., Hughes, D., Hartmann, A., Stoehr, R. and Catto, J. 2010. Low frequency of epigenetic events in urothelial tumors in young patients. The Journal of Urology. 184 (2), pp. 459-463. https://doi.org/10.1016/j.juro.2010.03.131
Chondrocyte p21(WAF1/CIP1) expression is increased by dexamethasone but does not contribute to dexamethasone-induced growth retardation in vivo
Owen, H., Ahmed, S. and Farquharson, C. 2009. Chondrocyte p21(WAF1/CIP1) expression is increased by dexamethasone but does not contribute to dexamethasone-induced growth retardation in vivo. Calcified Tissue International and Musculoskeletal Research. 85 (4), pp. 326-334. https://doi.org/10.1007/s00223-009-9276-0
Distinct microRNA alterations characterize high- and low-grade bladder cancer
Catto, J., Miah, S., Owen, H., Bryant, H., Myers, K., Dudziec, E., Larré, S., Milo, M., Rehman, I., Rosario, D., Di Martino, E., Knowles, M., Meuth, M., Harris, A. and Hamdy, F. 2009. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Research. 69 (21), pp. 8472-8481. https://doi.org/10.1158/0008-5472.CAN-09-0744
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair
Stordal, B. and Davey, R. 2009. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Cancer Chemotherapy and Pharmacology. 63 (4), pp. 661-672. https://doi.org/10.1007/s00280-008-0783-x
Citations, citations everywhere but did anyone read the paper? [Letter to the Editor]
Stordal, B. 2009. Citations, citations everywhere but did anyone read the paper? [Letter to the Editor]. Colloids and surfaces. B, Biointerfaces. 72 (2), pp. 312 -312. https://doi.org/10.1016/j.colsurfb.2009.04.001
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1
Stordal, B. and Davey, R. 2009. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Current Cancer Drug Targets. 9 (3), pp. 354-365. https://doi.org/10.2174/156800909788166592
Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes
Owen, H., Roberts, S., Ahmed, S. and Farquharson, C. 2008. Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes. American Journal of Physiology - Endocrinology and Metabolism. 294 (6), pp. E1023-E1034. https://doi.org/10.1152/ajpendo.00586.2007
Identification of a novel splice variant of the haloacid dehalogenase: PHOSPHO1
Roberts, S., Owen, H. and Farquharson, C. 2008. Identification of a novel splice variant of the haloacid dehalogenase: PHOSPHO1. Biochemical and Biophysical Research Communications. 371 (4), pp. 872-876. https://doi.org/10.1016/j.bbrc.2008.04.163
Platinum resistance needs the mythbusters [Letter to the Editor]
Stordal, B. and Davey, R. 2008. Platinum resistance needs the mythbusters [Letter to the Editor]. Toxicology letters. 180 (3), p. 230. https://doi.org/10.1016/j.toxlet.2008.07.003
A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome
Stordal, B. and Davey, R. 2008. A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome. IUBMB Life. 60 (3), pp. 180-184. https://doi.org/10.1002/iub.24
The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438
Owen, H., Miner, J., Ahmed, S. and Farquharson, C. 2007. The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Molecular and Cellular Endocrinology. 264 (1-2), pp. 164-70. https://doi.org/10.1016/j.mce.2006.11.006
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship
Stordal, B., Pavlakis, N. and Davey, R. 2007. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treatment Reviews. 33 (8), pp. 688-703. https://doi.org/10.1016/j.ctrv.2007.07.013
Understanding cisplatin resistance using cellular models
Stordal, B. and Davey, M. 2007. Understanding cisplatin resistance using cellular models. IUBMB Life. 59 (11), pp. 696-699. https://doi.org/10.1080/15216540701636287
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review
Stordal, B., Pavlakis, N. and Davey, R. 2007. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treatment Reviews. 33 (4), pp. 347-357. https://doi.org/10.1016/j.ctrv.2007.01.009
Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance
Stordal, B., Peters, G. and Davey, R. 2006. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance. Genes, Chromosomes & Cancer. 45 (12), pp. 1094-105. https://doi.org/10.1002/gcc.20373